XOMA to Present at the JMP Securities Healthcare Conference

BERKELEY, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Dr. Paul Rubin, the company's Senior Vice President, Research and Development and Chief Medical Officer, is scheduled to present at JMP Securities 2013 Healthcare Conference on July 9, 2013 at 3:30 p.m. ET.

A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 30 days following the presentation.

About XOMA Corporation

XOMA is a biotechnology company focused on advancing its portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research. Its antibody research and development centers on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. XOMA is developing its lead product candidate, gevokizumab (IL-1 beta modulating antibody), with SERVIER through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific discoveries led to establishment of the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs), which could have a major effect on the treatment of insulin-related diseases.

More detailed information can be found at www.xoma.com. 

CONTACT: Company and Investor Contacts:
         Ashleigh Barreto
         510-204-7482
         barreto@xoma.com

         Juliane Snowden
         The Oratorium Group, LLC
         jsnowden@oratoriumgroup.com

         Media Contact:
         Canale Communications
         Carolyn Hawley
         619-849-5375
         carolyn@canalecomm.com

Released July 2, 2013